Education
About Us
Working with TipRanks
Follow Us
InflaRx NV (IFRX)
NASDAQ:IFRX
IFRX Stock Chart & Stats
$1.02
-$0.16(-6.27%)
At close: 4:00 PM EST
$1.02
-$0.16(-6.27%)
Day’s Range― - ―
52-Week Range$0.71 - $2.82
Previous CloseN/A
Volume66.97K
Average Volume (3M)5.31M
Market Cap
$66.74M
Enterprise Value$39.46M
Total Cash (Recent Filing)$44.65M
Total Debt (Recent Filing)$970.86K
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Mar 19, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding67,133,270
10 Day Avg. Volume728,036
30 Day Avg. Volume5,308,164
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)2.29
Price to Sales (P/S)847.69
P/FCF Ratio-2.89
Enterprise Value/Market Cap0.59
Enterprise Value/Revenue628.01
Enterprise Value/Gross Profit-7.64
Enterprise Value/Ebitda-1.00
Forecast
1Y Price Target
$11.14Price Target Upside992.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.81
Revenue Forecast (FY)$88.30K
Bulls Say, Bears Say
Bulls Say
Financial StabilityInflaRx boasts a commercial asset and strong cash balance providing runway into 2027, suggesting the stock is undervalued and has significant potential upside.
Market PotentialThe stock is considered undervalued and has significant potential upside on a near-term horizon.
Therapeutic EfficacyINF904 therapy results in rapid and clinically meaningful reductions in abscesses and nodules, draining tunnels, and improved HiSCR responses that continued to deepen four weeks after the treatment period.
Bears Say
Efficacy ConcernsOverall, we don't think a clear efficacy signal jumps out as of now, and so we agree with the Company's plans to seek a partnership for this indication moving forward.
Market ChallengesBiogen discontinued the development of its mAb against C5aR1, which could indicate challenges in this area that might also affect Inflarx.
Study LimitationsThe caveats are that this is a small study, there's no placebo arm, and targeting the C5a pathway has already failed in 2 placebo-controlled Phase 2 trials for HS.
InflaRx News
IFRX FAQ
What was InflaRx NV’s price range in the past 12 months?
InflaRx NV lowest stock price was $0.71 and its highest was $2.81 in the past 12 months.
What is InflaRx NV’s market cap?
InflaRx NV’s market cap is $66.74M.
When is InflaRx NV’s upcoming earnings report date?
InflaRx NV’s upcoming earnings report date is Mar 19, 2026 which is in 104 days.
How were InflaRx NV’s earnings last quarter?
InflaRx NV released its earnings results on Oct 30, 2025. The company reported -$0.209 earnings per share for the quarter, missing the consensus estimate of -$0.175 by -$0.034.
Is InflaRx NV overvalued?
According to Wall Street analysts InflaRx NV’s price is currently Undervalued.
Does InflaRx NV pay dividends?
InflaRx NV does not currently pay dividends.
What is InflaRx NV’s EPS estimate?
InflaRx NV’s EPS estimate is -0.17.
How many shares outstanding does InflaRx NV have?
InflaRx NV has 67,133,270 shares outstanding.
What happened to InflaRx NV’s price movement after its last earnings report?
InflaRx NV reported an EPS of -$0.209 in its last earnings report, missing expectations of -$0.175. Following the earnings report the stock price went down -4.348%.
Which hedge fund is a major shareholder of InflaRx NV?
Currently, no hedge funds are holding shares in IFRX
InflaRx Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.14 (992.16% Upside)
$11.14 (992.16% Upside)
Blogger Sentiment
Bullish
IFRX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 751.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 4.4%
Last 30 Days ▲ 104.4%
Last 30 Days ▲ 104.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-52.84%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-13.92%
Trailing 12-Months
Company Description
InflaRx NV
InflaRx (IFRX) is a biopharmaceutical company focused on developing novel therapeutics to treat autoimmune and inflammatory diseases. The company specializes in the discovery and clinical development of monoclonal antibodies that target the complement system, a part of the immune system that plays a crucial role in inflammation. InflaRx's lead product candidates, including IFX-1, are designed to inhibit the complement component C5a, which is implicated in various inflammatory conditions. The company operates within the healthcare sector, specifically in the biotechnology space, aiming to address unmet medical needs in patients with conditions like hidradenitis suppurativa and other inflammatory diseases.
IFRX Stock 12 Month Forecast
Average Price Target
$11.14
▲(992.16% Upside)
Technical Analysis
Oramed Pharm
―
Atara Biotherapeutics
―
Anixa Biosciences
―
Clene
―
Acumen Pharmaceuticals
―
Ownership Overview
―
Insiders
0.07% Mutual Funds
20.59% Other Institutional Investors
79.34% Public Companies and
Individual Investors